TempraMed Technologies Ltd., a Canada-based leading company, has entered a particular exclusive commercial distribution partnership with Guri A.A.O. to sell and promote (market) TempraMed’s full product line throughout the Israeli retail market. This partnership deal represents a meaningful and valuable milestone in TempraMed’s global commercialisation smart strategy. Following this deal, the company elevated its spindle from a direct-to-consumer online model to B2B medical payers and a large-scale retail pharmacy range (engagements).
This positive shift, a transformation into the business along with the TempraMed’s long-standing strategy to mitigate patient acquisition costs, unify its temperature control solutions straight into the standard of care terms and enhance global access for an infinite patient group seeking temperature-based precious medication is commendable.
Guri is one of the proven excellent distributors who is among the top five distributors in Israel’s retail sector, and has long experience of above 50 years of successful journey in industry leadership. Guri distributes the massive volume of internationally popular, well-recognised brands such as Truvia natural sweeteners, a Cargill brand and GSK/Haleon oral care products. These brands share a deep and long-term relationship with Guri, still standing tall and promising with 2,500 of Israel’s largest pharmacy chains, supermarkets, other independent pharmacies and HMOs.
By confirming and clarifying the exclusive rights to TempraMed’s forthcoming temperature concern medical storage products and VIVI line, Guri will be an important one to introduce TempraMed’s solutions to its regional market. The market is popular for the comprehensive consumer engagement and early acceptance, and excellence of advanced medical technologies in chronic care and diabetes management.
The CEO of TempraMed, Ron Nagar, said, “With the expansion, our focus has sharpened to equip TempraMed’s technology within the clinical and retail spectrum where the care is already in fruition for patients. By collaborating with a top-class distributor like Guri reflect our special transition and dream to shift from a digital B2C model to B2B payor channels and pharmacy-led distribution.”
Ron added, “This is an important and valuable step towards naming a temperature-safe medication storage as the proven global golden standard, one that reduces waste, improves safety and outcomes. This is a relief for those patient groups that are highly dependent on temperature-sensitive therapies each day.”
Additionally, TempraMed also announced its third-quarter financial results and other updates on the existing announced offering.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
